Healthcare Equipment and Supplies
Company Overview of NeoTract, Inc.
NeoTract, Inc. develops and manufactures minimally invasive medical devices that address unmet needs in the field of urology. It offers UroLift System, a minimally invasive device to treat the men suffering from an enlarged prostate; relieve prostate obstruction and open the urethra; and relieve lower urinary tract symptoms due to benign prostatic hyperplasia. Its products are available throughout the United States, Europe, Australia, Canada, Mexico, and South Korea. The company was founded in 2004 and is based in Pleasanton, California with business locations in the United States, Australia, Europe, Denmark, Finland, Germany, Italy, the Netherlands, Norway, Spain, Sweden, Turkey, and the Un...
4473 Willow Road
Pleasanton, CA 94588
Founded in 2004
Key Executives for NeoTract, Inc.
President, CEO & Director
Co-Founder & VP of Professional Education
Compensation as of Fiscal Year 2017.
NeoTract, Inc. Key Developments
Teleflex Incorporated, Neotract, Inc. - M&A Call
Sep 5 17
To discuss that Teleflex Incorporated to acquire NeoTract, Inc
NeoTract, Inc. Announces Publication of Data from Benign Prostatic Hyperplasia Study
Jun 30 17
NeoTract, Inc. has announced the publication of the five-year results of the company's pivotal, randomized L.I.F.T. IDE study in the Canadian Journal of Urology. The study evaluated the safety and effectiveness of the company's novel UroLift System as a treatment for patients with symptomatic benign prostatic hyperplasia (BPH), or enlarged prostate. Results of the five-year L.I.F.T. study demonstrate that UroLift System treatment provides: A highly tolerable, minimally invasive procedural experience; Rapid reduction of symptoms after the procedure while preserving sexual function; Sustained effect, with IPSS (International Prostate Symptom Score) and Qmax (peak urinary flow rate) remaining 36% and 44% improved from baseline, respectively; Quality of life (QoL) score improvement of 50% over five years; and a durable treatment with a low surgical retreatment rate of 2-3% per year. The prospective, randomized, sham controlled, blinded study of the safety and effectiveness of the procedure was performed across 19 centers in the US, Canada and Australia. A total of 430 subjects were assessed, from which 206 were deemed eligible and enrolled between February and December of 2011. Of those assessed for randomization, 23 (5.3%) were excluded for an obstructive median lobe. Subjects were excluded only if it was deemed cystoscopically that lateral lobe distraction would not mitigate obstruction. The trial participants were men 50 years of age or older, with International Prostate Symptom Scores of 13 or higher. The subjects were followed 5 years and assessed on symptom response (IPSS), quality of life (IPSS QOL and BPH Impact Index, BPHII), peak flow rate (Qmax), sexual function (International Index of Erectile Function, IIEF, and Male Sexual Health Questionnaire for Ejaculatory Dysfunction, MSHQ-EjD) and adverse events. Nearly 40 million men in the US are affected by BPH, which occurs with advancing age when the prostate gland that surrounds the male urethra becomes enlarged and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life. Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the alternative has traditionally been surgery that cuts, heats or removes prostate tissue to open the blocked urethra.
Neotract Inc. Announces Cigna Coverage for the UroLift System for Enlarged Prostate
May 11 17
NeoTract, Inc. announced that Cigna, a global health service company that provides insurance for over 14 million Americans, has established coverage for the UroLift System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH). The UroLift System is a treatment that has demonstrated that it can get men off BPH medications and allow them to avoid major surgery, while preserving sexual function. Results of the five-year L.I.F.T. study demonstrate that the UroLift System treatment provides a highly tolerable, minimally invasive procedural experience, rapid reduction of symptoms after the procedure while preserving sexual function, and sustained improvements in QoL (Quality of Life) score, IPSS (International Prostate Symptom Score), and Qmax (peak urinary flow rate). In addition, the retreatment rate was just 2%-3% per year, among the lowest of all BPH treatments.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 5, 2017
December 29, 2016